1.重庆医科大学附属第二医院药学部,重庆 400010
2.重庆大学附属沙坪坝医院药学部,重庆 401300
Received:30 October 2025,
Revised:2026-02-11,
Accepted:12 February 2026,
Published:15 March 2026
移动端阅览
何璐,朱鸣阳,胡晓蕾,等.某市紧密型县域医共体集中(云)审方中心建设现状及发展建议 Δ[J].中国药房,2026,37(05):578-583.
HE Lu,ZHU Mingyang,HU Xiaolei,et al.Research on the current situation and development suggestions of centralized (cloud) prescription review center of the close-knit county-level medical consortium in a city[J].ZHONGGUO YAOFANG,2026,37(05):578-583.
何璐,朱鸣阳,胡晓蕾,等.某市紧密型县域医共体集中(云)审方中心建设现状及发展建议 Δ[J].中国药房,2026,37(05):578-583. DOI: 10.6039/j.issn.1001-0408.2026.05.05.
HE Lu,ZHU Mingyang,HU Xiaolei,et al.Research on the current situation and development suggestions of centralized (cloud) prescription review center of the close-knit county-level medical consortium in a city[J].ZHONGGUO YAOFANG,2026,37(05):578-583. DOI: 10.6039/j.issn.1001-0408.2026.05.05.
目的
2
调研某市已建成和筹建中的紧密型县域医共体集中(云)审方中心(简称“审方中心”)实际建设和运行情况,为提高审方中心建设质量提供参考。
方法
2
采用线上问卷收集某市51家已建成和筹建中的审方中心的基本情况、经费来源、人才管理、制度建设、审方规则维护、处方审核、处方点评和审方中心数据利用情况以及当前面临的困难,并进行数据汇总分析。
结果
2
共计回收有效问卷51份,包括32家已建成和19家筹建中的审方中心。在已建成的32家审方中心中,建设经费来源途径为财政经费拨款的占比最高,为56.25%;仅25.00%的审方中心药师的资质完全符合国家规范要求;审方规则月均维护条目数大于10条的审方中心的占比仅为55.00%;处方审核工作对门诊处方实现了全覆盖,但有37.50%的审方中心仅能支持单张处方合理性审核,50.00%的审方中心尚不支持调阅检验检查结果辅助审方;有40.62%的审方中心尚未常规开展对基层医疗机构的处方点评;审方中心数据主要用于用药监测。在筹建中的19家审方中心中,有63.16%都没有经费来源。
结论
2
该市审方中心在运行和建设过程中,普遍存在经费短缺、协同激励机制缺乏和人手不足等问题。建议国家尽快出台审方中心建设的统一标准,各地卫生健康行政部门结合区域实际制定配套政策,明确考核指标。
OBJECTIVE
2
To investigate the actual construction and operation status of established and under-construction centralized (cloud) prescription review centers (shortened for “prescription review center”) of close-knit county-level medical consortium in a certain city, so as to provide reference for improving the construction quality of the prescription review center.
METHODS
2
An online questionnaire survey was conducted to collect the data from 51 established and under-construction prescription review center in the city, covering basic information, funding sources, talent management, system construction, review rule maintenance, prescription review practices, prescription evaluation, data utilization, and current challenges. The collected data were summarized and analyzed.
RESULTS
2
A total of 51 valid questionnaires were retrieved, covering 32 established and 19 under-construction prescription review center. Among the 32 established prescription review centers, the main funding sources for their construction came from government financial allocations, accounting for 56.25%. Only 25.00% of prescription review center had review pharmacists who fully met national qualification requirements, and just 55.00% updated more than 10 review rule entries per month on average. Outpatient prescription verification realized full coverage, but 37.50% of prescription review centers only supported rationality verification of single prescriptions, and 50.00% could not retrieve laboratory and examination results to assist in prescription review. Additionally, 40.62% of prescription review center had not regularly conducted prescription evaluations for primary care institutions. The data from prescription review center was mainly used to support medication monitoring. Among the 19 prescription review centers currently in the planning stage, 63.16% had no identified funding sources.
CONCLUSIONS
2
The operation and construction of prescription review center in the city face challenges, such as funding shortages, absence of collaborative incentive mechanisms, and insufficient manpower.It is suggested that the state should issue a unified standard for the construction of the prescription review center as soon as possible, and local health administrative departments should formulate supporting policies and clarify assessment indicators in combination with the actual situation of the region.
FU M Y , GONG Z W , ZHU Y Z , et al . Inappropriate antibiotic prescribing in primary healthcare facilities in China:a nationwide survey,2017-2019 [J ] . Clin Microbiol Infect , 2023 , 29 ( 5 ): 602 - 609 .
邱文涛 , 张敏 , 徐锦锋 . 2023年某院住院部处方用药不合理情况分析 [J ] . 医药前沿 , 2025 , 15 ( 23 ): 143 - 145 .
顾婕 , 丁兰萍 , 马祝悦 , 等 . 处方审核系统的构建及应用效果 [J ] . 中国药物与临床 , 2025 , 25 ( 15 ): 954 - 959,953 .
刘思琪 , 杨延 , 何志超 , 等 . 儿童处方前置审核系统的规则优化与效果分析 [J ] . 中国药物与临床 , 2025 , 25 ( 16 ): 1023 - 1032 .
谷娇娇 , 张晟肇 , 赵江林 , 等 . 区域化处方审核平台构建与运用 [J ] . 中国药业 , 2025 , 34 ( 19 ): 38 - 42 .
宁艳阳 . 改革不只是给基层配上药那么简单 [N ] . 健康报 , 2025-08-22 (6).
国家卫生健康委 , 工业和信息化部 , 国家医保局 , 等 . 关于改革完善基层药品联动管理机制 扩大基层药品种类的意见 [EB/OL ] .( 2024-11-14 )[ 2026-01-14 ] . https://www.gov.cn/zhengce/zhengceku/202411/content_6988935.htm https://www.gov.cn/zhengce/zhengceku/202411/content_6988935.htm .
重庆市卫生健康委 . 重庆市全面推动紧密型区县域医疗卫生共同体高质量发展实施方案 [EB/OL ] .( 2024-12-24 )[ 2026-01-14 ] . https://admin.cq.gov.cn/zwgk/zfxxgkml/szfwj/xzgfxwj/szfbgt/202412/t20241226_14025458.html https://admin.cq.gov.cn/zwgk/zfxxgkml/szfwj/xzgfxwj/szfbgt/202412/t20241226_14025458.html .
江西省卫生健康委 . 江西出台医共体“双中心”建设标准 [EB/OL ] .( 2025-10-22 )[ 2026-01-14 ] . https://hc.jiangxi.gov.cn/jxswsjkwyh/mtbd/content/content_198089010219- 3655808.html https://hc.jiangxi.gov.cn/jxswsjkwyh/mtbd/content/content_198089010219-3655808.html .
国家卫生健康委员会 , 国家中医药管理局 , 中央军委后勤保障部 . 关于印发医疗机构处方审核规范的通知 [EB/OL ] .( 2018-6-29 )[ 2026-01-14 ] . https://www.nhc.gov.cn/yzygj/c100068/201807/03df2450431348e18feb3701c199- 262d.shtml https://www.nhc.gov.cn/yzygj/c100068/201807/03df2450431348e18feb3701c199-262d.shtml .
中国医院协会 . 医疗机构药事管理与药学服务 第 2 - 2 部分:临床药学服务 处方审核[EB/OL ] .[ 2026-01-14 ] . https://www.duodown.com/biaozhun/2906123.html https://www.duodown.com/biaozhun/2906123.html .
中国医院协会 . 医疗机构药事管理与药学服务 第 4 - 9 部分:药事管理 处方点评[EB/OL ] .[ 2026-01-14 ] . https://max.book118.com/html/2024/0819/5230311103011311.shtm https://max.book118.com/html/2024/0819/5230311103011311.shtm .
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
